Tier 3 — preclinical

Quercetin in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies

Xiao-Wen Zhang, Jia-Yue Chen, Defang Ouyang, Jia-Hong Lu
International journal of molecular sciences 2020 21(2):493

Bibliography

PubMed
PMID 31941000
PubMed Central
PMC7014205
DOI
10.3390/ijms21020493
Funding
Indexed grant support: FDCT-0110/2018/A3, FDCT-024-2017-AMJ, FDCT-092-2015-A3 — Macau SAR; NSFC-31500831 — Grants of China; MYRG2016-0019-ICMS-QRCM — University of Macau grant. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: The authors declare that there is no conflict of interests.

Study snapshot

DesignSystematic review of animal Alzheimer-model studies
ModelPreclinical evidence synthesis
Sample14 preclinical studies
InterventionQuercetin across animal models and regimens
DurationLiterature available at the review cutoff
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2020, this source examined brain, cognition and sleep. Design: Systematic review of animal Alzheimer-model studies. Sample/model: 14 preclinical studies. The exposure or intervention was Quercetin across animal models and regimens. Follow-up or treatment period: Literature available at the review cutoff.

The review reports favorable behavioral and biological findings in experimental Alzheimer models.

Low methodological quality, missing sample-size calculations, and animal-model limitations constrain translation. It does not demonstrate dementia prevention or treatment in humans.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review reports favorable behavioral and biological findings in experimental Alzheimer models.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin across animal models and regimens; Literature available at the review cutoff.

What this study can and cannot tell us

  • Low methodological quality, missing sample-size calculations, and animal-model limitations constrain translation. It does not demonstrate dementia prevention or treatment in humans.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Effects of quercetin and its derivatives in in vivo models of neuroinflammation: A systematic review and meta-analysis
Michele Goulart Dos Santos et al. · Neural regeneration research · 2026
Tier 3
Effects of quercetin in preclinical models of Parkinson's disease: A systematic review
Camila de Oliveira Vian et al. · Basic & clinical pharmacology & toxicology · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology